The Use of Intravitreal Injection of Triamcinolone Acetonide in Diabetic Patients to Reduce Diabetic Macular Edema
- Conditions
- Diabetic macular edemaEye - Diseases / disorders of the eye
- Registration Number
- ACTRN12613000249752
- Lead Sponsor
- suez canal university hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 19
The major eligibility criteria for the study eyes included the following: (1) best-corrected visual acuity letter score between 20/40 and 20/320; (2) definite retinal thickening resulting from DME on clinical examination involving the center of the macula assessed to be the main cause of visual loss; (3) retinal thickness measured with optical coherence tomography (OCT) of 250 micro m or more in the central subfield ;(4) Grid laser treatment was done at least three months earlier.
Principal exclusion criteria included; (1) prior treatment with intravitreal corticosteroids (at any time), peribulbar steroid injection within the prior 6 months, or pars plana vitrectomy (at any time); (2) a history of glaucoma or steroid-induced IOP elevation that required IOP-lowering treatment; (3) average intraocular pressure of 23 mm Hg or more after three preinjection evaluations; (4) eyes with ischemic maculopathy and (5) patients with foveal traction detected with OCT.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method control of diabetic macular edema (DME), detection of DME was done with Optical Coherence Tomography.( medical Equipment)[six months follow up after injection.]
- Secondary Outcome Measures
Name Time Method follow up of intraocular pressure (IOP) rise after injection. measurement was done by Goldmann applanation Tonometer mounted on slit lamp..<br>[follow up of intraocular pressure rise after injection for six months after injection]